IgG-VHH bispecific fusion antibodies : challenges and opportunities as therapeutic agents
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Expert opinion on biological therapy - 24(2024), 4 vom: 29. Apr., Seite 203-206 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Madsen, Andreas V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Bispecific |
|---|
| Anmerkungen: |
Date Completed 29.04.2024 Date Revised 29.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14712598.2024.2336068 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370338537 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370338537 | ||
| 003 | DE-627 | ||
| 005 | 20240429232116.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240329s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14712598.2024.2336068 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1392.xml |
| 035 | |a (DE-627)NLM370338537 | ||
| 035 | |a (NLM)38544310 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Madsen, Andreas V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IgG-VHH bispecific fusion antibodies |b challenges and opportunities as therapeutic agents |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.04.2024 | ||
| 500 | |a Date Revised 29.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a IgG | |
| 650 | 4 | |a IgG-VHH fusion | |
| 650 | 4 | |a VHH | |
| 650 | 4 | |a antibody | |
| 650 | 4 | |a bispecific | |
| 650 | 4 | |a bsAb | |
| 650 | 4 | |a fusion protein | |
| 650 | 7 | |a Antibodies, Bispecific |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Kristensen, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Goletz, Steffen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on biological therapy |d 2001 |g 24(2024), 4 vom: 29. Apr., Seite 203-206 |w (DE-627)NLM116190124 |x 1744-7682 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:4 |g day:29 |g month:04 |g pages:203-206 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14712598.2024.2336068 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 4 |b 29 |c 04 |h 203-206 | ||